Keryx Licenses Japanese Rights For Zerenex To Japan Tobacco In $100 Million Deal
This article was originally published in PharmAsia News
Keryx Biopharmaceuticals got a major boost Sept. 26 in its effort to bring the Phase II hyperphosphatemia candidate Zerenex to the worldwide market by signing a licensing agreement potentially worth up to $100 million with Japan Tobacco and its subsidiary, Torii Pharmaceutical
You may also be interested in...
An NDA for the tablet form of the follow-on chronic kidney disease therapy is pending at FDA.
Ilypsa’s lead candidate, ILY1001, for treatment of hyperphosphatemia in chronic kidney disease, complements Amgen’s anemia agents.
A 2008 launch of the first-in-class diabetic nephropathy treatment is possible.